Arrowstreet Capital
AMRX icon

Arrowstreet Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Arrowstreet Capital’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.79M Sell
334,758
-189,209
-36% -$2.59M ﹤0.01% 1247
2026
Q1 		$6.51M Sell
523,967
-566,457
-52% -$7.61M ﹤0.01% 1078
2025
Q4 		$13.7M Sell
1,090,424
-207,338
-16% -$2.37M 0.01% 836
2025
Q3 		$13M Sell
1,297,762
-399,463
-24% -$3.59M 0.01% 874
2025
Q2 		$13.7M Sell
1,697,225
-96,228
-5% -$725K 0.01% 807
2025
Q1 		$15M Buy
1,793,453
+252,395
+16% +$2.11M 0.01% 683
2024
Q4 		$12.2M Sell
1,541,058
-527,921
-26% -$4.43M 0.01% 764
2024
Q3 		$17.2M Buy
2,068,979
+1,269,641
+159% +$9.93M 0.01% 577
2024
Q2 		$5.08M Buy
799,338
+167,430
+26% +$1.06M ﹤0.01% 836
2024
Q1 		$3.83M Buy
631,908
+420,234
+199% +$2.37M ﹤0.01% 969
2023
Q4 		$1.28M Sell
211,674
-590,914
-74% -$2.63M ﹤0.01% 1057
2023
Q3 		$3.39M Sell
802,588
-110,386
-12% -$412K ﹤0.01% 741
2023
Q2 		$2.83M Buy
912,974
+231,957
+34% +$494K ﹤0.01% 750
2023
Q1 		$947K Buy
681,017
+183,543
+37% +$365K ﹤0.01% 1077
2022
Q4 		$990K Buy
+497,474
New +$1.12M ﹤0.01% 1029
2022
Q2 		– Sell
-349,320
Closed -$1.46M – 1215
2022
Q1 		$1.46M Buy
349,320
+146,754
+72% +$650K ﹤0.01% 871
2021
Q4 		$970K Buy
202,566
+111,276
+122% +$555K ﹤0.01% 1167
2021
Q3 		$487K Sell
91,290
-157,870
-63% -$795K ﹤0.01% 1422
2021
Q2 		$1.28M Sell
249,160
-262,592
-51% -$1.49M ﹤0.01% 1471
2021
Q1 		$3.44M Buy
+511,752
New +$2.84M ﹤0.01% 1336
2020
Q4 		– Sell
-114,213
Closed -$443K – 2267
2020
Q3 		$443K Sell
114,213
-1,174,869
-91% -$5.02M ﹤0.01% 2050
2020
Q2 		$6.14M Buy
1,289,082
+1,089,819
+547% +$4.49M 0.01% 971
2020
Q1 		$693K Buy
199,263
+5,527
+3% +$23.4K ﹤0.01% 1435
2019
Q4 		$934K Buy
+193,736
New +$673K ﹤0.01% 1353

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Arrowstreet Capital's AMRX Position: Q2 2026 in Review

Arrowstreet Capital reduced its Amneal Pharmaceuticals (AMRX) stake by 36% in Q2 2026, selling an estimated $2.59M and leaving 334,758 shares worth $5.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1247.

Arrowstreet Capital first reported a position in AMRX in Q4 2019 and has held it in 24 quarters since. The position peaked at $17.2M in Q3 2024. 308 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Arrowstreet Capital held 334,758 shares of Amneal Pharmaceuticals worth $5.79M as of Q2 2026.
  • Arrowstreet Capital sold 189,209 Amneal Pharmaceuticals shares in Q2 2026, an estimated $2.59M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1247 holding.
  • Arrowstreet Capital first reported a position in Amneal Pharmaceuticals in Q4 2019 and has held it in 24 quarters since.
  • Arrowstreet Capital's Amneal Pharmaceuticals position peaked at $17.2M in Q3 2024.
  • 308 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.